2004, Number 3
<< Back Next >>
Med Cutan Iber Lat Am 2004; 32 (3)
Hydroxyurea Induced Ulcer
Fagundo GE, García BM, Guimerá-Martín NF, Rodríguez GF, Noda CA, Sánchez GR
Language: Spanish
References: 13
Page: 121-123
PDF size: 132.19 Kb.
ABSTRACT
Hydroxyurea (HU) is an antitumoral agent used to treat hematological disorders mainly chronic myeloproliferative diseases. Although hydroxyurea is relatively well tolerated, different adverse effects involving skin such as hyperpigmentation, erythema and desquamation of the face and hands, alopecia, atrophy, nail changes, and genitalia, oral mucosa and legs ulcers have been described during long term therapy. We describe a patient with a 13 years of evolution policitemia vera presenting a painful ulcer on the external left leg maleolus, after 5 years having HU. We review the pathogenesis of HU leg ulcers, their diagnosis and differential diagnosis.
REFERENCES
Layton A, Sheehan-Dare R, Goodfield M, Cotterill J. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989;121: 647-53.
Kennedy BJ, Smith LR, Goltz Rw. Skin changes secondary to hydroxyurea therapy. Arch Dermatol 1975; 111:183-87.
Nguyen TV, Margolis DJ. Hydroxyurea and lower leg ulcers. Cutis 1993;52:217-9.
Vassallo C, Passamonti F, Merante S, Ardigò M, Nolli G, Mangiacavalli S et al. Muco-cutaneous change during long-term therapy with hydroxyurea in chronic myeloid leukemia. Clin Exp Dermatol 2001; 26:141-8.
Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesine G, Mandeli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia.Tumori 1986;72:317-21.
Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long- term hydroxyurea therapy. J Am Acad Dermatol 1998;39:372-4.
Salmon-Ehr V, Leborgne G, Vilque JP, Potron G, Bernard P. Secondary cutaneous effects of hydroxyurea: prospective study of 26 patients from a dermatologic consultation. Rev Med Interne 2000;21: 30-4.
Best PJ, Daoud MS, Pittelkow MR, Pettit RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998;128:29-32.
Velez A, García-Aranda JM, Moreno JC. Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? J Eur Acad Dermatol 1999;12:243-4.
Bader U, Banyai M, Boni R, Burg G, Hafner J. Leg ulcers in patients with myeloproliferative disorders: disease- or treatment- related?. Dermatology 2000;200:45-8.
Kido M, Tago O, Fujiwara H, Ito M, Niwano H. Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostaglandin E1 and pentoxifylline. Br J Dermatol 1998;139:1124-6.
Kato N, Kimura K, Yasukawa K, Yoshida K. Hydroxyurea-related ulcers in a patient with chronic myelogenous leukaemia: a case report and rewiew of the literature. J Dermatol 1999;26:56-62.
Flores F, Eaglstein WA, Kirsner RS. Hydroxyurea-induced leg ulcers treated with Apligraf. Ann Intern Med 2000;132:417-8.